Stay updated with breaking news from Dan Budwick. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
07.03.2022 - Initial data from pivotal FIREFLY-1 study with DAY101 (tovorafenib) expected in June 2022 Targeted enrollment achieved in pivotal FIREFLY-1 study Topline results from pivotal FIREFLY-1 study expected in Q1 2023 Current cash provides runway into ...
/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2021. Cash and...
CAMBRIDGE, Mass., Feb. 09, 2022 -- Beam Therapeutics Inc. , a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive... | February 9, 2022
Adagio Therapeutics Summarizes ADG20 Neutralizing Activity Against SARS-CoV-2 Variants and Outlines Initiatives to Address Omicron GlobeNewswire January 12, 2022 Recent Publications by Several Independent Laboratories Show ADG20 Has Neutralizing Activity with Potency Comparable to Other Antibodies that Retain Activity Against Omicron WALTHAM, Mass., Jan. 12, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc.,...
Press release content from Globe Newswire. The AP news staff was not involved in its creation.